The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice: Effect of adrenalectomy

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 621-626

  Cheng, John B ^a   Watson, John W ^a   Pazoles, Christopher J ^a   Eskra, James D ^a   Griffiths, Richard J ^a   Cohan, Victoria L ^a   Turner, Claudia R ^a   Showell, Henry J ^a   Pettipher, E Roy ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ATIZORAM; CYCLIC AMP; DIPYRIDAMOLE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PROPRANOLOL; ROLIPRAM; SKB 94120; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

ADRENALECTOMY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; ENZYME REGULATION; IMMUNOMODULATION; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENALECTOMY; ANIMALS; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; EPINEPHRINE; HUMANS; KINETICS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIROXICAM; PROPRANOLOL; PURINONES; PYRIMIDINONES; THROMBOXANE B2; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VINCA ALKALOIDS;

EID: 0030942485     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ABSOOD, A., CHEN, D. AND HAKANSON, R.: Neuropeptides of the vasoactive intestinal peptide/helodermin/pituitary adenylate cyclase activating peptide family elevate plasma cAMP in mice: Comparison with a range of other regulatory peptides. Regul. Pept. 40: 311-323, 1992.
2. BARNARD, J. W., SEIBERT, A. F., RAVI PRASSAD, V., SMART, D. A., STRADA, S. J., TAYLOR, A. E. AND THOMPSON, W. J.: Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor. J. Appl. Physiol. 77: 774-781, 1994.
3. BEAVO, J.: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75: 725-748, 1995.
4. BEAVO, J. A., CONTI, M. AND HEASLIP, R. J.: Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46: 399-405, 1994.
5. CANDITO, M., ALBERTINI, M., POLITANO, S., DEVILLE, A., MARIANI, R. AND CHAMBON, P.: Plasma catecholamine levels in children. J. Chrom. 617: 304-307, 1993.
6. CHENC, J. B., GOLDFIEN, A., BALLARD, P. L. AND ROBERTS, J. M.: Glucocorticoid increases beta-adrenergic receptors in fetal rabbit lung. Endocrinology 107: 1646-1648, 1980.
7. CHENG, J. B., PILLAR, J. S., MARSHALL, S. C., GABEL, C. A. AND SHIRLEY, J. T.: Characterization of Type IV phosphodiesterase (PDE IV) in U-937 cells: Activation of cyclic AMP (cAMP) efflux caused by inhibition of PDE IV (Abstract). FASEB J. 8: A371, 1994.
8. COHAN, V. L., SHOWELL, H. L., PETTIPHER, E. R., FISHER, D. A., PAZOLES, C. J., WATSON, J. W., TURNER, C. R. AND CHENG, J. B.: In vitro pharmacology of the novel phosphodiesterase Type VI inhibitor CP-80,633. J. Pharmacol. Exp. Ther. 278: 1356-1361, 1996.
9. CONTI, M., NEMOZ, G., SETTE, C. AND VICINI, E.: Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocinol. Rev. 16: 370-389, 1995.
10. FRASER, C. M. AND VENTER, J. C.: The synthesis of β-adrenergic receptors in human lung cells: Induced by glucocorticoids. Biochem. Biophys. Res. Commun. 94: 390-395, 1980.
11. FEHR, T. F., DICKINSON, E. S., GOLDMAN, S. J. AND SLAKEY, L. L.: Cyclic AMP efflux is regulated by occupancy of the adenosine receptor in pig aortic smooth muscle cell. J. Biol. Chem. 265: 10974-10980, 1990.
12. GRISWOLD, D. E., WEB, E. F., BRETON, J., WHILTE, J. R., MARSHALL, P. J. AND TORPHY, T. J.: Effect of a selective type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 17: 333-344, 1993.
13. HADLEY, A. J., FLACK, J. D. AND BUCKINGHAM, J. C.: Potentiation of cyclic AMP mediated corticotrophin (ACTH) release by denbufylline in vivo and in vitro. Br. J. Pharmacol. 104: 313P, 1991.
14. HANIFIN, J. M., CHAN, S. C., CHENG, J. B., HENDERSON, W. R. JR., KIRBY, D. S. AND WEINER, E. S.: In vitro and in vivo anti-inflammatory effects of Type IV phosphodiesterase inhibitors in atopic dermatitis. J. Invest. Dermatol. 107: 51-56, 1996.
15. KALSNER, S.: Mechanisms of potentiation of contractor response to catecholamines by methylxanthines in aortic strips. Br. J. Pharmacol. 43: 379-388, 1971.
16. KALSNER, S., FREW, R. D. AND SMITH, G. H.: Mechanism of methylxanthine sensitization of norepinephrine responses in a coronary artery. Am. J. Physiol. 228: 1720-1707, 1975.
17. KAMINSKY, N. I., BROADUS, A. E., HARDMAN, J. G., JONES, D. J., BALL, J. H., SUTHERLAND, E. W. AND LIDDLE, G. W.: Effect of parathyroid hormone on plasma and urinary adenosine 3′,5′monophosphate in man. J. Clin. Invest. 49: 2387-2395, 1970.
18. MANO, K., AKBARDAZEH, A. AND TOWNLEY, R. G.: Effect of hydrocortisone on β-adrenergic receptors in lung membrane. Life Sci. 25: 1925-1930, 1979.
19. MINKOFF, J. R., GRANT, B. F. AND MARCUS, R.: Plasma cyclic AMP response to calcitonin: A potential marker of bone turnover. Bone 6: 285-290, 1985.
20. NISTRUP MADSEN, S.: Influence of thyroid function on plasma cyclic AMP response to i.v. glucagon. Acta Endocinol. 85: 760-768, 1977.
21. O'DONNELL, J. M.: Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 264: 1168-1178, 1993.
22. PETTIPHER, E. R., LABASI, J., SALTER, E. D., STAM, E. J., CHENG, J. B. AND GRIFFITHS, R. J.: Regulation of tumour necrosis factor production by adrenal hormones in vivo: Insights into the antiinflammatory activity of rolipram. Br. J. Pharmacol. 117: 1530-1534, 1996.
23. PRABHAKAR, U., LIPSHUTZ, D., BARTUS, J., SLIVJAK, M., SMITT, I., LEE, E. J. AND KSSER, K.: Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16: 805-816, 1994.
24. ROBINSON, G. A., BUTCHER, R. W. AND SUTHERLAND, E. R.: Cyclic AMP, pp. 17-142, Academic Press, N.Y., 1971.
25. SCUVEE-MOREAU, J., GIESBERS, I. AND DREESE, A.: Effect of rolipram, a phosphodiesterase inhibitor and potential antidepressant, on the firing rate of central monoaminerigic neurons in the rat. Arch. Intl. Pharmacodyn. Ther. 288: 43-49, 1987.
26. SEMMLER, J. H., WACHTEL, H. AND ENDRES, S.: The specific type IV phosphodiesterase inhibitor suppresses tumor necrosis factor a production by human mononuclear cells. Int. J. Immunopharmacol. 15: 409-413, 1993.
27. TORPHY, T. AND UNDEM, B.: Phosphodiesterase inhibitors. New opportunities for the treatment of asthma. Thorax 46: 512-523, 1991.
28. TURNER, C. R., COHAN, V. L., CHENG, J. B., SHOWELL, H. L., PAZOLES, C. J. AND WATSON, J. W.: The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase IV (PDE IV). J. Pharmacol. Exp. Ther. 278: 1349-1355, 1996.
29. TURNER, C. R., ESSER, K. M. AND WHEELDON, E. B.: Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ., Shock 39: 237-245, 1993.
30. UNDERWOOD, D. C., MATTHEW, J. K., OSBORN, R. R., NOVAK, L. B., BOCHNOWICZ, S. AND MEUNIER, L. D.: Catecholamines and β-adrenoceptor influences on airway reactivity to antigen in guinea pigs. Intl. Arch. Allergy Immunol. 109: 286-294, 1996.
31. WACHTEL, H. AND SCHNEIDER, H. H.: Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesis of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacol. 25: 1119-1126, 1986.
32. WEINREICH, D. AND UNDEM, B. J.: Immunological regulation of synaptic transmission in isolated guinea pig autonomic ganglia. J. Clin. Invest. 79: 1529-1532, 1987.